Anti-CD45.2 Mouse Monoclonal Antibody (Clone 104-2)


Anti-CD45.2 Mouse Monoclonal Antibody (Clone 104-2)

Antigen:                                     Mouse CD45.2 (Ly5.2)
Clone Name:                            104-2
Isotype:                                      Mouse IgG2a (Kappa Light Chain)
Application(s)*:                       Flow Cytometry, Immunofluorescence Microscopy, Immunoprecipitation
Reactivity*:                                Mouse

* As reported in the literature and other commercial supplier websites


Clone 104-2 reacts with CD45 (Leukocyte Common Antigen) on leukocytes of mouse strains that express the CD45.2 alloantigen, including A, AKR, BALB⁄c, CBA⁄Ca, CBA⁄J, C3H⁄He, C57BL, C57BR, C57L, C58, DBA⁄1, DBA⁄2, NZB, SWR, and 129. It has been reported not to react with leukocytes from mouse strains expressing the CD45.1 alloantigen.


This antibody was derived in 1981 by injection of thymocytes and splenocytes from B10.S mice into SJL mice. Splenocytes from these SJL mice were fused with NS-1 cells to generate hybridomas.


  • Edward Boyse, MD, formerly of Memorial Sloan Kettering
  • Fung-Win Shen, PhD

Key References

  • Shen FW (1981) Monoclonal antibodies to mouse lymphocyte differentiation alloantigens. Monoclonal Antibodies and T-Cell Hybridomas: Perspectives and Technical Advances. Hämmerling GJ, Hämmerling U and Kearney JF, editors. Elsevier/North-Holland Biomedical Press, Amsterdam. 25-31 (ISBN: 9780444803511)
  • Yakura H et al. (1983) On the function of Ly-5 in the regulation of antigen-driven B cell differentiation. Comparison and contrast with Lyb-2. Journal of Experimental Medicine 157: 1077-88 (PubMed ID: 6220106)

Licensing Information

This hybridoma may be licensed nonexclusively for commercial purposes. Please note that Anti-CD45.1 Mouse Monoclonal Antibody (Clone A-20) is also available for licensing from MSK. For more information, please contact [email protected].

Additional Information

Purified antibody may be available for sale through the Memorial Sloan Kettering Antibody & Bioresource Core Facility. Please email [email protected] for further information.

Stage of Development

Ready to use